SARS-CoV-2 rS (Novavax)

N/A

Report date: 2025/05/27 16:02:13

Base Information

Drug NameSARS-CoV-2 rS (Novavax)
Drug Alias NameSARS-CoV-2 recombinant spike protein nanoparticle vaccineSARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine (Novavax)COVID-19 vaccine (Novavax)SARS-CoV-2 rS/Matrix M1-AdjuvanCoronavirus vaccine(Novavax) +[18] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsInfluenza, Human
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2021/12/20
Country/TerritoryUnited StatesSingaporePuerto Rico +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovavaxTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979Serum Institute Of India Pvt LtdEuropean Commission +[10] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsInfluenza, Human
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A